Affordable Access

deepdyve-link
Publisher Website

cIAP1/2 are involved in the radiosensitizing effect of birinapant on NSCLC cell line in vitro.

Authors
  • Sun, Hao1
  • Du, Yanan2
  • Yao, Ming1
  • Wang, Qin1
  • Ji, Kaihua1
  • Du, Liqing1
  • Xu, Chang1
  • He, Ningning1
  • Wang, Jinhan1
  • Zhang, Manman1
  • Liu, Yang1
  • Wang, Yan1
  • Wen, Kaixue3
  • Liu, Qiang1
  • 1 Institute of Radiation Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China. , (China)
  • 2 Tianjin Center for Disease Control and Prevention, Tianjin, China. , (China)
  • 3 Shanxi Academy of Medical Sciences, Shanxi Bethune Hospital, Shanxi, China. , (China)
Type
Published Article
Journal
Journal of Cellular and Molecular Medicine
Publisher
Wiley (Blackwell Publishing)
Publication Date
May 03, 2021
Identifiers
DOI: 10.1111/jcmm.16526
PMID: 33939305
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Tumour radioresistance is a major problem for cancer radiation therapy. To identify the underlying mechanisms of this resistance, we used human non-small cell lung cancer (NSCLC) cell lines and focused on the Inhibitor of Apoptosis Protein (IAP) family, which contributes to tumourigenesis and chemoresistance. We investigated the possible correlation between radioresistance in six NSCLC cell lines and IAP protein levels and tested the radiosensitizing effect of birinapant in vitro, a molecule that mimics the second mitochondria-derived activator of caspase. We found that birinapant-induced apoptosis and inhibited the proliferation of NSCLC cells after exposure to radiation. These effects were induced by birinapant downregulation of cIAP protein levels and changes of cIAP gene expression. Overall, birinapant can inhibit tumour growth of NSCLC cell lines to ironizing radiation and act as a promising strategy to overcome radioresistance in NSCLC. © 2021 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.

Report this publication

Statistics

Seen <100 times